brca1 protein

Summary

Summary: The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)

Top Publications

  1. ncbi Cancer susceptibility and the functions of BRCA1 and BRCA2
    Ashok R Venkitaraman
    University of Cambridge, CRC Department of Oncology, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Cell 108:171-82. 2002
  2. pmc 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks
    Samuel F Bunting
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cell 141:243-54. 2010
  3. ncbi A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
    Y Miki
    Department of Medical Informatics, University of Utah Medical Center, Salt Lake City 84132
    Science 266:66-71. 1994
  4. pmc 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
    Peter Bouwman
    Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Struct Mol Biol 17:688-95. 2010
  5. ncbi BRCA1 and BRCA2: different roles in a common pathway of genome protection
    Rohini Roy
    Molecular Biology Program and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Nat Rev Cancer 12:68-78. 2012
  6. pmc Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral
    S V Tavtigian
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
    J Med Genet 43:295-305. 2006
  7. pmc BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
    Y Wang
    Verna and Mars McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Genes Dev 14:927-39. 2000
  8. pmc Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks
    Yaron Galanty
    The Wellcome Trust and Cancer Research UK Gurdon Institute, and Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK
    Nature 462:935-9. 2009
  9. ncbi Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
    I Garcia-Higuera
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Department of Pediatrics, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 7:249-62. 2001
  10. pmc BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair
    J Ross Chapman
    Wellcome Trust and Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK
    J Cell Sci 125:3529-34. 2012

Research Grants

  1. Regulation of BRCA1 Function by Protein Phosphatase 1
    Lih Ching Hsu; Fiscal Year: 2009
  2. Development of BRCA1-mimetic drugs for breast cancer
    Eliot M Rosen; Fiscal Year: 2013
  3. Role of EZH2 in Breast Cancer Progression
    Celina G Kleer; Fiscal Year: 2013
  4. HTS Assay to Identify Small Molecule Activators of BRCA1 Expression
    Lisa M Harlan-Williams; Fiscal Year: 2012
  5. BRCA1 and Familial Pancreatic Cancer
    Alison Klein; Fiscal Year: 2007
  6. MOLECULAR EPIDEMIOLOGY OF BRCA1 RELATED BREAST NEOPLASIA
    Anne Blackwood Chirchir; Fiscal Year: 2002
  7. ANTIBODY BASED ASSAY TO DEFECT BRCA1 PROTEIN TRUNCATIONS
    TIMOTHY BYRNE; Fiscal Year: 1999
  8. BRCA1 Function
    Jeffrey Parvin; Fiscal Year: 2006
  9. Centrosomes and BRCA1
    Jeffrey D Parvin; Fiscal Year: 2010
  10. Unique BRCA1 transcriptional response leading to repair
    Wafik El Deiry; Fiscal Year: 2006

Detail Information

Publications297 found, 100 shown here

  1. ncbi Cancer susceptibility and the functions of BRCA1 and BRCA2
    Ashok R Venkitaraman
    University of Cambridge, CRC Department of Oncology, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Cell 108:171-82. 2002
    ..Here, I examine what is known about the biological functions of the BRCA proteins and ask how their disruption can induce susceptibility to specific types of cancer...
  2. pmc 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks
    Samuel F Bunting
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cell 141:243-54. 2010
    ..Our results illustrate that HR and NHEJ compete to process DNA breaks that arise during DNA replication and that shifting the balance between these pathways can be exploited to selectively protect or kill cells harboring Brca1 mutations...
  3. ncbi A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
    Y Miki
    Department of Medical Informatics, University of Utah Medical Center, Salt Lake City 84132
    Science 266:66-71. 1994
    ..Identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology...
  4. pmc 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
    Peter Bouwman
    Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Struct Mol Biol 17:688-95. 2010
    ..We find reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of our findings...
  5. ncbi BRCA1 and BRCA2: different roles in a common pathway of genome protection
    Rohini Roy
    Molecular Biology Program and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Nat Rev Cancer 12:68-78. 2012
    ..As discussed here, the proteins work in concert to protect the genome from double-strand DNA damage during DNA replication...
  6. pmc Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral
    S V Tavtigian
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
    J Med Genet 43:295-305. 2006
    ..However, clinical testing methods with high sensitivity for deleterious mutations in these genes also detect many unclassified variants, primarily missense substitutions...
  7. pmc BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
    Y Wang
    Verna and Mars McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Genes Dev 14:927-39. 2000
    ..Collectively, these results suggest that BRCA1 may function as a coordinator of multiple activities required for maintenance of genomic integrity during the process of DNA replication and point to a central role for BRCA1 in DNA repair...
  8. pmc Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks
    Yaron Galanty
    The Wellcome Trust and Cancer Research UK Gurdon Institute, and Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK
    Nature 462:935-9. 2009
    ..These findings thus identify PIAS1 and PIAS4 as components of the DDR and reveal how protein recruitment to DSB sites is controlled by coordinated SUMOylation and ubiquitylation...
  9. ncbi Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
    I Garcia-Higuera
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Department of Pediatrics, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 7:249-62. 2001
    ..The FANCD2 protein, therefore, provides the missing link between the FA protein complex and the cellular BRCA1 repair machinery. Disruption of this pathway results in the cellular and clinical phenotype common to all FA subtypes...
  10. pmc BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair
    J Ross Chapman
    Wellcome Trust and Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK
    J Cell Sci 125:3529-34. 2012
    ..Furthermore, the genomic instability exhibited by BRCA1-deficient cells might result from a failure to efficiently exclude 53BP1 from such regions during S phase...
  11. pmc CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
    Maximina H Yun
    Division of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK
    Nature 459:460-3. 2009
    ....
  12. pmc Genetic steps of mammalian homologous repair with distinct mutagenic consequences
    Jeremy M Stark
    Molecular Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Mol Cell Biol 24:9305-16. 2004
    ..These results imply that the proper genetic interplay of repair factors is essential to limit the mutagenic potential of DSB repair...
  13. pmc BRCA1 and its toolbox for the maintenance of genome integrity
    Michael S Y Huen
    Department of Anatomy, The University of Hong Kong, Laboratory Block, 21 Sassoon Road, Hong Kong
    Nat Rev Mol Cell Biol 11:138-48. 2010
    ..Thus, BRCA1 is emerging as the master regulator of the genome through its ability to execute and coordinate various aspects of the DNA damage response...
  14. pmc DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains
    Xiaochun Yu
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Mol Cell Biol 24:9478-86. 2004
    ..Taken together, these data not only implicate CtIP as a critical player in cell cycle checkpoint control but also provide molecular mechanisms by which BRCA1 controls multiple cell cycle transitions after DNA damage...
  15. ncbi The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress
    Joanna R Morris
    Department of Medical and Molecular Genetics, King s College London, Guy s Medical School Campus, London SE1 9RT, UK
    Nature 462:886-90. 2009
    ..These data demonstrate that the SUMOylation pathway plays a significant role in mammalian DNA damage response...
  16. pmc BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair
    Samuel F Bunting
    Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Cell 46:125-35. 2012
    ..BRCA1 therefore has two separate roles in ICL repair that can be modulated by manipulating NHEJ, whereas FANCD2 provides a key activity that cannot be bypassed by ablation of 53BP1 or Ku...
  17. ncbi 53BP1, a mediator of the DNA damage checkpoint
    Bin Wang
    Verna and Mars McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Science 298:1435-8. 2002
    ....
  18. pmc A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Nat Genet 42:885-92. 2010
    ..80, 95% CI 0.74-0.87, P(trend) = 1.1 × 10⁻⁷..
  19. pmc Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155
    Suhwan Chang
    Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA
    Nat Med 17:1275-82. 2011
    ..Our findings demonstrate a new mode of tumor suppression by BRCA1 and suggest that miR-155 is a potential therapeutic target for BRCA1-deficient tumors...
  20. ncbi A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    Alan Ashworth
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 26:3785-90. 2008
    ..This provides the basis for a novel synthetic lethal approach to cancer therapy...
  21. pmc BRCA1 tumour suppression occurs via heterochromatin-mediated silencing
    Quan Zhu
    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA
    Nature 477:179-84. 2011
    ..We propose that the role of BRCA1 in maintaining global heterochromatin integrity accounts for many of its tumour suppressor functions...
  22. ncbi RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins
    Niels Mailand
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK 2100, Copenhagen, Denmark
    Cell 131:887-900. 2007
    ..These data suggest that MDC1-mediated and RNF8-executed histone ubiquitylation protects genome integrity by licensing the DSB-flanking chromatin to concentrate repair factors near the DNA lesions...
  23. ncbi BRCA1 dysfunction in sporadic basal-like breast cancer
    N C Turner
    Chester Beatty Laboratories, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 26:2126-32. 2007
    ..0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer...
  24. pmc A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes
    Douglas F Easton
    Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge, UK
    Am J Hum Genet 81:873-83. 2007
    ..In addition to their utility for improved genetics counseling of patients and their families, the global assessment reported here will be invaluable for validation of functional assays, structural models, and in silico analyses...
  25. ncbi Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair
    Longchuan Chen
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 283:7713-20. 2008
    ....
  26. ncbi DNA double-strand breaks: signaling, repair and the cancer connection
    K K Khanna
    The Queensland Institute of Medical Research, and Department of Pathology, University of Queensland, PO Royal Brisbane Hospital, Brisbane, Queensland, Australia
    Nat Genet 27:247-54. 2001
    ..Moreover, we discuss how tumor suppressor proteins such as p53, ATM, Brca1 and Brca2 have been linked to such pathways, and how accumulating evidence is connecting deficiencies in cellular responses to DNA DSBs with tumorigenesis...
  27. pmc Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair
    Junran Zhang
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA
    Mol Cell Biol 24:708-18. 2004
    ..The BRCA1 protein becomes phosphorylated in response to DNA damage, but the effects of phosphorylation on recombinational repair ..
  28. pmc High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
    Sven Rottenberg
    Division of Molecular Biology and Centre for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:17079-84. 2008
    ....
  29. pmc A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency
    Liu Cao
    Translational Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Cell 35:534-41. 2009
    ..These observations may have important implications for Brca1-mediated tumor formation as well as for the molecular pathway leading from genomic instability to organismal aging...
  30. pmc RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly
    Michael S Y Huen
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell 131:901-14. 2007
    ..Together, our study implicates RNF8 as a novel DNA-damage-responsive protein that integrates protein phosphorylation and ubiquitylation signaling and plays a critical role in the cellular response to genotoxic stress...
  31. pmc A guide for functional analysis of BRCA1 variants of uncertain significance
    Gael A Millot
    Institut Curie, CNRS, UMR 3244 Université Pierre et Marie Curie, Paris, France
    Hum Mutat 33:1526-37. 2012
    ..Importantly, these methods may provide a framework for genome-wide pathogenicity assignment...
  32. ncbi BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
    Miquel Taron
    Medical Oncology Service, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Hum Mol Genet 13:2443-9. 2004
    ..020) compared with those in the top quartile. BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer...
  33. ncbi mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer
    Jia Wei
    Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, 321 Zhongshan Rd, Nanjing, China
    J Natl Cancer Inst 103:1552-6. 2011
    ..03 to 5.97, P = .037). Survival in patients receiving second-line docetaxel-based chemotherapy showed a similar trend with PIAS1 and PIAS4 mRNA expression levels, although the associations for PIAS4 were not statistically significant...
  34. pmc Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
    Hum Mol Genet 20:3304-21. 2011
    ..27 and 0.30, respectively). The identification of SNPs at 6q25.1 associated with breast cancer risk for BRCA1 mutation carriers will lead to a better understanding of the biology of tumour development in these women...
  35. pmc Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
    Fergus J Couch
    Departments of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 21:645-57. 2012
    ..We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)...
  36. ncbi BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance
    Rinske Drost
    Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam
    Cancer Cell 20:797-809. 2011
    ..These findings point to hypomorphic activity of the BRCA1-C61G protein that, although unable to prevent tumor development, affects response to therapy...
  37. ncbi Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice
    Xiaoling Xu
    Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Development 130:2001-12. 2003
    ..Thus, our study revealed an essential role of Brca1 in DNA-damage repair and crossing-over of homologous chromosomes during spermatogenesis...
  38. pmc The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection
    Kara A Coleman
    Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6160, USA
    J Biol Chem 286:13669-80. 2011
    ..We propose a model in which the BRCA1-RAP80 complex limits nuclease accessibility to DSBs, thus preventing excessive end resection and potentially deleterious homology-directed DSB repair mechanisms that can impair genome integrity...
  39. pmc Links between genome integrity and BRCA1 tumor suppression
    Mischa L Li
    Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd, Philadelphia, PA 19104 6160, USA
    Trends Biochem Sci 37:418-24. 2012
    ..This review summarizes and highlights recent insights into the molecular events responsible for BRCA1 tumor suppression, emphasizing the DNA repair function of BRCA1 as a nexus between its roles in cancer development and therapy...
  40. pmc PALB2 is an integral component of the BRCA complex required for homologous recombination repair
    Shirley M H Sy
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 106:7155-60. 2009
    ....
  41. pmc Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress
    R S Tibbetts
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Genes Dev 14:2989-3002. 2000
    The BRCA1 gene encodes a tumor suppressor that is mutated in 50% of familial breast cancers. The BRCA1 protein has been implicated in the DNA damage response, as DNA damage induces the phosphorylation of BRCA1 and causes its recruitment ..
  42. ncbi BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells
    Kerri L Chock
    Department of Pathology, John A Burns School of Medicine, University of Hawaii and Cancer Research Center of Hawaii, Honolulu, Hawaii 96813, USA
    Cancer Res 70:8782-91. 2010
    ....
  43. ncbi Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation
    X Xu
    Genetics of Development and Disease Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Genet 22:37-43. 1999
    ..Our results demonstrate that disruption of Brca1 causes genetic instability and triggers further alterations, including the inactivation of p53, that lead to tumour formation...
  44. pmc BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity
    Reena Shakya
    Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA
    Science 334:525-8. 2011
    ..The BRCA1 protein displays E3 ubiquitin ligase activity, and this enzymatic function is thought to be required for tumor ..
  45. pmc A new non-catalytic role for ubiquitin ligase RNF8 in unfolding higher-order chromatin structure
    Martijn S Luijsterburg
    Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
    EMBO J 31:2511-27. 2012
    ....
  46. ncbi The BRCT domain is a phospho-protein binding domain
    Xiaochun Yu
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Science 302:639-42. 2003
    ..Thirteen additional BRCT domains also preferentially bind phospho-peptides rather than nonphosphorylated control peptides. These data imply that the BRCT domain is a phospho-protein binding domain involved in cell cycle control...
  47. ncbi BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis
    Jennifer E Quinn
    Department of Oncology, Cancer Research Centre, Queen s University Belfast, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, U K
    Cancer Res 63:6221-8. 2003
    ..Therefore, our data suggest that BRCA1 acts as a differential modulator of apoptosis depending on the nature of the cellular insult...
  48. pmc Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays
    Megan S Lee
    Department of Biochemistry, School of Systems Molecular Medicine, University of Alberta, Edmonton, Alberta, Canada
    Cancer Res 70:4880-90. 2010
    ..associated with a large set of 117 distinct BRCA1 missense variants within the essential BRCT domain of the BRCA1 protein that have been documented in individuals with a family history of breast or ovarian cancer...
  49. pmc Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer
    Silvia Casadei
    Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Cancer Res 71:2222-9. 2011
    ..Given this mutation prevalence and risk, consideration might be given to clinical testing of PALB2 by complete genomic sequencing for familial breast cancer patients with wild-type sequences at BRCA1 and BRCA2...
  50. pmc BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP
    Xiaochun Yu
    Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Genes Dev 20:1721-6. 2006
    ..Thus, we propose that BRCA1 can regulate the functions of its substrates through nonproteasomal pathways that do not involve substrate degradation...
  51. ncbi A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
    T T Paull
    Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 0540, USA
    Curr Biol 10:886-95. 2000
    ..Recently it has been reported that a member of the histone H2A family, H2AX, becomes extensively phosphorylated within 1-3 minutes of DNA damage and forms foci at break sites...
  52. ncbi BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
    Anne Renee Hartman
    Department of Internal Medicine Oncology, Stanford University Medical Center, Stanford, California 94305 5151, USA
    Nat Genet 32:180-4. 2002
    ..Defects in the NER pathway in BRCA1-associated breast cancers may be causal in tumor development, suggesting a multistep model of carcinogenesis...
  53. ncbi Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    Clin Cancer Res 17:1160-8. 2011
    ..However, the presence of EGFR mutations can only imperfectly predict outcome. We hypothesized that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways...
  54. pmc Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction
    Antonis C Antoniou
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
    Cancer Res 70:9742-54. 2010
    ..Our findings indicated that these risk differences might be sufficient to influence the clinical management of mutation carriers...
  55. pmc Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity
    H Ruffner
    The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 98:5134-9. 2001
    ..Furthermore, we propose that the analysis of the Ub ligase activity of RING-domain mutations identified in patients may constitute an assay to predict predisposition to cancer...
  56. ncbi Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years
    Kathleen E Malone
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Res 66:8297-308. 2006
    ....
  57. pmc Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics
    Mollie H Wright
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    Breast Cancer Res 10:R10. 2008
    ..Whether cancer stem cells occur in BRCA1-associated breast cancer and contribute to therapeutic response is not known...
  58. ncbi The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly
    Vladimir Joukov
    Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cell 127:539-52. 2006
    ..These observations reveal a previously unrecognized function of BRCA1/BARD1 in mitotic spindle assembly that likely contributes to its role in chromosome stability control and tumor suppression...
  59. ncbi Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation
    R Hakem
    Amgen Institute, Toronto, Ontario, Canada
    Nat Genet 16:298-302. 1997
    ..5. The fact that mutation of neither p53 nor p21 completely rescued Brca1 (5-6) embryos suggests that their lethality is likely due to a multi-factorial process...
  60. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
    ..2)...
  61. ncbi A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation
    Sara Alvarez
    Human Genetics Department, Molecular Pathology Programme, Spanish National Cancer Centre, c o Melchor Fernandez Almagro, 28029 Madrid, Spain
    Clin Cancer Res 11:1146-53. 2005
    ..This fact suggests that somatic BRCA1 inactivation could modify the profile of tumor progression in most of the BRCAX cases...
  62. ncbi A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability
    S X Shen
    Laboratory of Biochemistry and Metabolism, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncogene 17:3115-24. 1998
    ..We believe that the increased incidence of such additional mutations accounts for the mechanism of tumorigenesis associated with Brca1 mutations in humans...
  63. ncbi Genetic analysis of BRCA1 function in a defined tumor cell line
    R Scully
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Mol Cell 4:1093-9. 1999
    ..These data constitute the basis for a BRCA1 functional assay and suggest that efficient repair of double-strand DNA breaks is linked to BRCA1 tumor suppression function...
  64. ncbi Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan
    S S Li
    Institute of Biomedical Sciences, National Sun Yat Sen University, Kaohsiung, Taiwan, Republic of China
    Hum Genet 104:201-4. 1999
    ..All three deletions are predicted to generate frameshifts and to result in the premature termination of BRCA2 protein translation. Several genetic polymorphisms in both BRCA1 and BRCA2 genes were also detected in this investigation...
  65. pmc Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    PLoS ONE 4:e5133. 2009
    ..In an exploratory analysis, we also examined the effect of RAP80 and Abraxas mRNA levels...
  66. ncbi The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer
    Goran Jonsson
    Department of Oncology, CREATE Health Strategic Center for Translational Cancer Research, Lund University, Skåne Department of Oncology, Skane University Hospital, Lund, Sweden
    Cancer Res 72:4028-36. 2012
    ..Together, our findings show the existence of genetic heterogeneity within the basal-like breast cancer subtype that is based upon BRCA1 status...
  67. ncbi Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
    L S Friedman
    Department of Molecular and Cell Biology and School of Public Health, University of California, Berkeley 94720
    Nat Genet 8:399-404. 1994
    ..The four families with both breast and ovarian cancer had chain termination mutations in the N-terminal half of the protein...
  68. ncbi The role of the BRCA1 tumor suppressor in DNA double-strand break repair
    Junran Zhang
    Department of Radiation Oncology, Washington University in St Louis, 4511 Forest Park Boulevard, St Louis, Missouri 63108, USA
    Mol Cancer Res 3:531-9. 2005
    ..Although the BRCA1 protein has been implicated in multiple cellular functions, the precise mechanism that determines its tumor suppressor ..
  69. ncbi Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas
    Socorro Maria Rodriguez-Pinilla
    Breast and Gynecological Cancer Group, Molecular Pathology Programme and Department of Human Genetics, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Clin Cancer Res 12:1533-9. 2006
    ..The aim of this study was to determine whether basal-like phenotype and fascin were related in both sporadic and familial tumors and with prognosis in node-negative sporadic breast cancers...
  70. pmc Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis
    Julia J Gorski
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast BT9 7BL and ALMAC Diagnostics, Craigavon BT63 5QD, UK
    Nucleic Acids Res 39:9536-48. 2011
    ..These data suggest a model, whereby BRCA1 is present on defined promoters as part of an inactive complex poised to respond to various genotoxic stimuli...
  71. ncbi BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer
    Judith E Carser
    Centre for Cancer Research and Cell Biology, Queens University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, N Ireland, UK
    Gynecol Oncol 123:492-8. 2011
    We investigated the relationship between BRCA1 protein expression by immunohistochemistry (IHC) and clinical outcome following platinum and platinum/taxane chemotherapy in sporadic epithelial ovarian cancer (EOC).
  72. pmc ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency
    Liu Cao
    Genetics of Development and Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    EMBO J 25:2167-77. 2006
    ..Our data highlight how accurate maintenance of genomic integrity is critical for the suppression of both aging and malignancy, and provide a further link between aging and cancer...
  73. pmc BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
    L Robertson
    Division of Genetics and Epidemiology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 106:1234-8. 2012
    ..We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer...
  74. ncbi Common genetic variants and cancer risk in Mendelian cancer syndromes
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, UK
    Curr Opin Genet Dev 20:299-307. 2010
    ....
  75. ncbi Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary
    Phillip J Whiley
    Queensland Institute of Medical Research, Brisbane, Australia
    Hum Mutat 32:678-87. 2011
    ....
  76. pmc BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history
    Gaik Theng Toh
    Cancer Research Initiatives Foundation CARIF, Outpatient Centre, Subang Jaya Medical Centre, Selangor, Malaysia
    PLoS ONE 3:e2024. 2008
    ..A proportion of these cases may be attributable, at least in part, to genetic components, but to date, the contribution of genetic components to breast cancer in many of Malaysia's ethnic groups has not been well-characterised...
  77. pmc Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Department of Public Health and Primary Care, Cancer Research UK Genetic Epidemiology Unit, University of Cambridge, Cambridge, UK
    Hum Mol Genet 18:4442-56. 2009
    ..There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not...
  78. pmc BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases
    Nancy Uhrhammer
    Laboratoire Diagnostic Génétique et Moléculaire, Centre Jean Perrin, 58 rue Montalembert, 63011 Clermont Ferrand, France
    Int J Med Sci 5:197-202. 2008
    ....
  79. pmc BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex
    Shinji Kawai
    Department of Oral Frontier Biology, Center for Frontier Oral Science, Osaka University Graduate School of Dentistry, Osaka 565 0871, Japan
    J Cell Biol 197:201-8. 2012
    ..Our findings also indicate novel functions of BRCA1 in miRNA biogenesis, which may be linked to its tumor suppressor mechanism and maintenance of genomic stability...
  80. ncbi BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer
    Julia J Gorski
    Department of Oncology, Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast BT9 7BL, N Ireland, UK
    Breast Cancer Res Treat 122:721-31. 2010
    ....
  81. pmc Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach
    Marc Tischkowitz
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Eur J Hum Genet 16:820-32. 2008
    ..However, it remains difficult to determine whether many single amino-acid (missense) changes in the BRCA1 protein that are frequently detected in the clinical setting are pathologic or not...
  82. ncbi PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2
    Fan Zhang
    Division of Experimental Hematology and Cancer Biology, Cincinnati Children s Research Foundation, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Mol Cancer Res 7:1110-8. 2009
    ....
  83. ncbi BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs
    Wenhong Fan
    Department of Radiation Oncology, Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 277:8061-7. 2002
    ..Physical associations of BRCA1 protein with transcription factors Oct-1 and NF-YA, which directly bind to the OCT-1 and CAAT motifs, are established ..
  84. ncbi High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer
    Petra van der Groep
    Department of Pathology, University Medical Center, 3508 GA, Utrecht, The Netherlands
    Breast Cancer Res Treat 111:475-80. 2008
    ..This points to an important role of hypoxia and its key regulator HIF-1alpha in hereditary breast carcinogenesis...
  85. pmc Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis
    Marcelo A Carvalho
    Risk Assessment, Detection, and Intervention Program, H Lee Moffitt Cancer Center, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Res 67:1494-501. 2007
    ..These results bring functional assays for BRCA1 closer to clinical applicability...
  86. ncbi Hallmarks of 'BRCAness' in sporadic cancers
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Nat Rev Cancer 4:814-9. 2004
    ..These common properties might have important implications for the clinical management of these cancers...
  87. pmc BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
    P Tassone
    Department of Experimental and Clincal Medicine, Magna Graecia University, Italy
    Br J Cancer 88:1285-91. 2003
    ..Full-length BRCA1 cDNA transfection of BRCA1-defective HCC1937 cells led to the reconstituted expression of BRCA1 protein in HCC1937/(WT)BRCA1-derived cell clone, but did not reduce tumour cell growth in soft agar...
  88. ncbi BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans
    Simon J Boulton
    DNA Damage Response Laboratory, Cancer Research UK, The London Research Institute, Clare Hall Laboratories, EN6 3LD, South Mimms, United Kingdom
    Curr Biol 14:33-9. 2004
    ..Our findings support a shared role for Ce-BRC-1 and Ce-BRD-1 in C. elegans DNA repair processes, and this role will permit studies of the BRCA1 pathway in an organism amenable to rapid genetic and biochemical analysis...
  89. pmc Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
    Ana M Mendes-Pereira
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    EMBO Mol Med 1:315-22. 2009
    ..The data we present here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours...
  90. ncbi Triple-negative breast cancer: therapeutic options
    Susan Cleator
    Oncology Department, St Mary s Hospital Trust, London, UK
    Lancet Oncol 8:235-44. 2007
    ....
  91. pmc Negative Regulation of AKT Activation by BRCA1
    Tao Xiang
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Cancer Res 68:10040-4. 2008
    ..Our results show that BRCA1 is a negative regulator of the AKT pathway and imply the significance of the BRCA1/AKT pathway in tumorigenesis...
  92. pmc Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells
    Saori Furuta
    Department of Biological Chemistry, College of Medicine, University of California, Irvine, CA 92697, USA
    Proc Natl Acad Sci U S A 102:9176-81. 2005
    ....
  93. pmc MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks
    Genze Shao
    Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Genes Dev 23:740-54. 2009
    ..These findings provide new molecular insights into how BRCA1 associates with independently assembled core protein complexes to maintain genome integrity...
  94. ncbi Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects
    B Evers
    Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Oncogene 25:5885-97. 2006
    ..These models will help to resolve yet unanswered questions and to translate our increasing knowledge of BRCA1 and BRCA2 biology into clinical practice...
  95. pmc Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers
    Laura N Burga
    Department of Surgery, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 69:1273-8. 2009
    ..These altered growth and differentiation properties may render BRCA1-mutant PMECs vulnerable to transformation and predispose to the development of ER-negative, EGFR-positive breast cancers...
  96. ncbi Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members
    Mads Thomassen
    Department of Clinical Genetics, Odense University Hospital, Soenderboulevard 29, 5000 Odense C, Denmark
    Breast Cancer Res Treat 132:1009-23. 2012
    ..Importantly, this study demonstrates the added value of collaboration between laboratories, and across disciplines, to collate and interpret information from clinical testing laboratories to consolidate patient management...
  97. pmc The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
    S R Young
    Women s College Research Institute, Department of Public Health, The University of Toronto, Toronto, Canada
    BMC Cancer 9:86. 2009
    ....
  98. ncbi Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients
    Sameer Mirza
    Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
    Life Sci 81:280-7. 2007
    ..This study also underscores the potential utility of DNA methylation based screening of serum (a surrogate for tumor DNA methylation) as a tool for detection of breast cancer...
  99. pmc NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control
    Bin Wang
    Department of Genetics, Howard Hughes Medical Institute, Center for Genetics and Genomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 23:729-39. 2009
    ..These findings provide a new perspective from which to view the BRCA1 A complex...
  100. pmc Pathology of hereditary breast cancer
    Petra van der Groep
    Department of Pathology, University Medical Center Utrecht, P O Box 85500, 3508 GA, Utrecht, The Netherlands
    Cell Oncol (Dordr) 34:71-88. 2011
    ..However, in still a part of familial hereditary breast cancers no relationship to any of these breast cancer susceptibility genes can be found. Research on new susceptibility genes is therefore ongoing...
  101. pmc Mutations in the BRCT binding site of BRCA1 result in hyper-recombination
    Seth M Dever
    Department of Radiation Oncology, Virginia Commonwealth University, Richmond, 23298, USA
    Aging (Albany NY) 3:515-32. 2011
    ..Thus, certain BRCA1 mutations that cause hyper-recombination instead of reduced DSB repair might lead to breast cancer...

Research Grants64

  1. Regulation of BRCA1 Function by Protein Phosphatase 1
    Lih Ching Hsu; Fiscal Year: 2009
    ..The loss of function of the BRCA1 gene is associated with breast and ovarian cancer. BRCA1 protein has been implicated in fundamental cellular functions, such as DMA repair, recombination, cell cycle ..
  2. Development of BRCA1-mimetic drugs for breast cancer
    Eliot M Rosen; Fiscal Year: 2013
    ..The goal of this research is to develop small molecule drug-like compounds that mimic the ability of the BRCA1 protein to insert into the estrogen receptor protein and inhibit estrogen action...
  3. Role of EZH2 in Breast Cancer Progression
    Celina G Kleer; Fiscal Year: 2013
    ..EZH2 transgenic mice develop epithelial intraductal hyperplasia with downregulation of nuclear BRCA1 protein and histological features recapitulating human disease...
  4. HTS Assay to Identify Small Molecule Activators of BRCA1 Expression
    Lisa M Harlan-Williams; Fiscal Year: 2012
    ..we propose Western blotting as a tertiary assay to assess validated hits for their ability to increase BRCA1 protein expression...
  5. BRCA1 and Familial Pancreatic Cancer
    Alison Klein; Fiscal Year: 2007
    ..The BRCA1 protein has been recently shown to be part of this same pathway...
  6. MOLECULAR EPIDEMIOLOGY OF BRCA1 RELATED BREAST NEOPLASIA
    Anne Blackwood Chirchir; Fiscal Year: 2002
    ..To date, scientific understanding of the function of the BRCA1 protein remains quite limited...
  7. ANTIBODY BASED ASSAY TO DEFECT BRCA1 PROTEIN TRUNCATIONS
    TIMOTHY BYRNE; Fiscal Year: 1999
    ..We used antibodies specific for both amino acid terminals of the BRCA1 protein, to demonstrate BRCA1 protein truncations by immunohistochemical analysis of matched ovarian tumor and normal ..
  8. BRCA1 Function
    Jeffrey Parvin; Fiscal Year: 2006
    ..In this way, these experiments will correlate BRCA1 protein domains to protein complexes and to functional effects...
  9. Centrosomes and BRCA1
    Jeffrey D Parvin; Fiscal Year: 2010
    ..has found that the function of this machine, called a centrosome, is controlled in breast cells by the BRCA1 protein. This project will dissect the workings of the centrosome and determine how BRCA1 controls its function in ..
  10. Unique BRCA1 transcriptional response leading to repair
    Wafik El Deiry; Fiscal Year: 2006
    ..We propose a hypothesis that following DNA damage rapid BRCA1 protein-DNA repair protein interactions and changes in localization lead to initiation of repair whereas a slower ..
  11. Biochemical Analysis of the BRCA1 Protein Complex
    Jun Qin; Fiscal Year: 2007
    ..goal of this competing continuation of grant (CA84199) is to understand the functions of tumor suppressor BRCA1 protein. We previously purified and identified a BRCA1 protein complex, BASC...
  12. Structural and Functional Characterization of BRCA1
    Rachel Klevit; Fiscal Year: 2007
    ..b>BRCA1 protein levels are up-regulated in proliferating breast epithelial cells, for example, during puberty, pregnancy, and ..
  13. BRCA 1 FUNCTION USING AN INDUCIBLE TRANSGENE
    EDWARD GUNTHER; Fiscal Year: 2003
    ..Recently, significant progress has been made in understanding the function of the BRCA1 protein through study of its expression patterns, cellular localization, molecular interactions, and potential roles ..
  14. FAMILIAL COLORECTAL NEOPLASIA COLLABORATIVE GROUP
    Noralane Lindor; Fiscal Year: 2007
    ..fs20\par \par } ..
  15. Ovarian Cancer and Mismatch Repair Deficiency
    Tuya Pal; Fiscal Year: 2009
    ..abstract_text> ..
  16. Protection Against Apoptosis by Scatter Factor
    Eliot Rosen; Fiscal Year: 2006
    ..Since SF may ameliorate certain forms of organ injury, understanding how it inhibits apoptosis may also provide new targets for the treatment of developmental, inflammatory, or toxic disorders. ..
  17. Apoptosis Signaling: BH3 to BH123 Proteins
    GOVINDASWAMY CHINNADURAI; Fiscal Year: 2008
    ..The knowledge gained would be valuable in modulating the activity of BAX in cancer and in degenerative diseases. ..
  18. Role of BRCA1 as a Human Tumor Suppressor Gene
    Eliot Rosen; Fiscal Year: 2008
    ..It is hoped that knowledge gained from these studies will lead to new approaches to cancer control and treatment. ..
  19. Weight Gain in African American Breast Cancer Survivors
    Chanita Hughes Halbert; Fiscal Year: 2005
    ..abstract_text> ..
  20. COX-2 Inhibitors, APC and Colon Cancer Prevention
    Kotha Subbaramaiah; Fiscal Year: 2009
    ..These studies will enhance our understanding of the mechanistic link between COX-2 and colorectal cancer and potentially assist us in optimizing the use of selective COX-2 inhibitors as therapy. ..
  21. African American Participation in Cancer Genetics Research
    Chanita Hughes Halbert; Fiscal Year: 2009
    ..This study will provide empirical data that can be used to develop more effective strategies for recruiting African Americans to participate in cancer genetics research that enhance decisions about study participation. ..
  22. FACTORS AFFECTING SURVIVAL OF YOUNG CANCER PATIENTS
    Kathleen Malone; Fiscal Year: 2002
    ....
  23. BRCA1 Modulates Estrogen Receptor Response in Breast Cancer
    Eliot Rosen; Fiscal Year: 2009
    ..In addition to their implications for breast cancer pathogenesis, these studies are of practical importance, since they may suggest novel approaches for breast cancer prevention and treatment. ..
  24. Cellular gene expression in HPV associated neoplasia
    Christopher Crum; Fiscal Year: 2002
    ..Such methods, if successful, could conceivably revolutionize the approach to cervical cancer prevention by broadening the conditions under which screening could be conducted. ..
  25. P21 INDUCTION BY BRCA2
    Fergus Couch; Fiscal Year: 2002
    ....
  26. BRCA1 TESTING IN A LARGE AFRICAN AMERICAN KINDRED
    Anita Kinney; Fiscal Year: 2003
    ..abstract_text> ..
  27. BRCA Genes in Breast Cancer Chemoprevention
    Eliot Rosen; Fiscal Year: 2009
    ..The latter may be particularly useful, since recent studies suggest that Tamoxifen may not protect women with BRCA1 mutations from developing breast cancer. ..
  28. PREVENTIVE ONCOLOGY AWARD
    Anita Kinney; Fiscal Year: 2003
    ..The University of Utah is a major academic institution with many distinguished scientists, and offers an excellent environment for Dr. Kinney to develop her skills and gain additional expertise to accomplish her goals. ..
  29. Multi-Dimensional Cultural Values
    Chanita Hughes Halbert; Fiscal Year: 2009
    ..This study will provide a psychometrically sound instrument that can be used in clinical and research settings to provide culturally sensitive care and interventions to ethnically and racially diverse populations. ..
  30. BH3-only protein BNIP3 in tumor progression
    GOVINDASWAMY CHINNADURAI; Fiscal Year: 2006
    ..Our results may also provide the experimental support to suggest that BNIP3 may be a new prognostic marker for human cancer. [unreadable] [unreadable]..
  31. Breast cancer prognostic factors/pathobiology
    Kathleen Malone; Fiscal Year: 2009
    ....
  32. Breast cancer and HRT: genetic susceptibility within th*
    Kathleen Malone; Fiscal Year: 2006
    ..abstract_text> ..
  33. Adiposity Related Biomarkers and Breast Tumor Size
    Kathleen Malone; Fiscal Year: 2002
    ..Findings from this study could begin to clarify a mechanism by which adiposity affects prognosis from breast cancer. ..
  34. PHENOTYPIC AND PSYCHOSOCIAL STUDY OF THE L1307K MUTATION
    Henry Lynch; Fiscal Year: 2004
    ....
  35. MOLECULAR PATHOGENESIS OF FANCONI ANEMIA
    ALAN D ANDREA; Fiscal Year: 2003
    ..For this specific aim, we will also test the nuclear FA protein complex for direct in vitro DNA binding activity or DNA repair activity, using model DNA templates. ..
  36. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2006
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  37. Abnormalities/Signal Transduction/Hematopoietic Disease
    ALAN D ANDREA; Fiscal Year: 2006
    ..abstract_text> ..
  38. MULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCER
    JEFFREY SALISBURY; Fiscal Year: 2002
    ..Separate facilities are available for animal housing, engineering, and classroom and lecture space. ..
  39. MODELING AND DOSIMETRY FOR RADIOLABELED ANTIBODY THERAPY
    George Sgouros; Fiscal Year: 2002
    ....
  40. Development of a genotyping assay using MAS technology
    Thomas Albert; Fiscal Year: 2002
    ..This system will have very high throughput, a low cost per SNP, and have accuracy >99 percent. ..
  41. HIN-1,A Novel Putative Breast Tumor Suppressor Gene
    Kornelia Polyak; Fiscal Year: 2006
    ..abstract_text> ..
  42. Bayesian Modeling and Optimal Design for Studies of Gene-Environment Association
    Edwin Iversen; Fiscal Year: 2009
    ..End of Abstract) ..
  43. ETIOLOGIC HETEROGENEITY IN LATE ONSET BREAST CANCER
    Timothy Rebbeck; Fiscal Year: 2001
    ..The results of these analyses will be used to attempt to elucidate the complex, multifactorial aetiology of late onset breast cancer. ..
  44. Parent Communication of BRCA1/2 Test Results to Children
    KENNETH TERCYAK; Fiscal Year: 2009
    ..Findings generated in this area offer a new paradigm within which to view and understand the psychosocial outcomes of predictive testing among tested parents and their nontested children. ..
  45. MOLECULAR MODELING OF DIAGNOSIS AND PROGNOSIS IN HNSCC
    Maria Worsham; Fiscal Year: 2009
    ..abstract_text> ..
  46. Regulation of the DNA damage response by the Mre11 complex
    JOHN HJ PETRINI; Fiscal Year: 2011
    ..Addressing these hypotheses will provide a foundation for understanding and improving responses to ionizing radiation in therapeutic settings. ..
  47. BARD1 AND BREAST CANCER PATHOGENESIS
    Richard Baer; Fiscal Year: 2001
    ....
  48. UCLA LASER SCANNING CYTOMETER
    Timothy Lane; Fiscal Year: 2001
    ..In addition, the members of the UCLA LSC Usere Group propose to act as an informational and technical resource to aid development of LSC related projects within the UCLA research community. ..
  49. Managed Care Penetration and Cancer Care
    Nancy Keating; Fiscal Year: 2003
    ..If managed care penetration is negatively associated with the delivery of care, interventions targeted toward policy-makers, providers, and patients will be needed to counteract the effects of market forces. ..
  50. Biomarker modulation/COX-2 inhibitor/Breast Cancer
    Banu Arun; Fiscal Year: 2003
    ..Ultimately, the development of non-hormonal chemoprevention agents, and identification of surrogate markers will allow us to plan large-scale, phase III chemoprevention studies with the endpoint of cancer incidence. ..
  51. BRCA1/2 Education for Mothers and Their Teen Daughters
    BETH PESHKIN; Fiscal Year: 2006
    ..It is expected that with respect to issues surrounding hereditary cancer susceptibility, the resource will result in improved knowledge, communication, and support among mothers and their teenage daughters. ..
  52. Structural, Computational and Epidemiologic Analyses of*
    Noah Kauff; Fiscal Year: 2006
    ..abstract_text> ..
  53. Centrosome Amplification in Human Breast Cancer
    JEFFREY SALISBURY; Fiscal Year: 2006
    ..The study of centrosome behavior is of fundamental importance to our understanding of the origin of malignant tumors and may reveal new targets for intervention or prevention of the development of breast cancer. ..
  54. ESTROGEN BIOSYNTHESIS AND UTERINE LEIOMYOMATA
    Serdar Bulun; Fiscal Year: 2007
    ..We predict that these studies will establish the critical role of P450arom in uterine leiomyomata and lead to identification of novel therapeutic targets. ..
  55. Distrust, Race/Ethnicity, and Predictive Genetic Testing
    Katrina Armstrong; Fiscal Year: 2005
    ....
  56. DNA Array-Based Exon Detection and Linkage Mapping
    TOM ALBERT; Fiscal Year: 2005
    ....
  57. Network for Translational Research: Optical Imaging
    Wafik El Deiry; Fiscal Year: 2007
    ..abstract_text> ..
  58. G2 CHECKPOINT CONTROL IN TRANSFORMED HUMAN CELLS
    CLARE MCGOWAN; Fiscal Year: 2008
    ..abstract_text> ..
  59. Microsimulation of anthracis-immune system interaction
    THOMAS KEPLER; Fiscal Year: 2005
    ....
  60. Breast Cancer, Radiation and the ATM-CHEK2 Pathway
    Jonine Bernstein; Fiscal Year: 2008
    ..Conduct a population-based case-control association study of 6 genes involved in the ATM-CHEK2 pathway to determine whether they are associated with an increased risk of radiation-induced contralateral breast cancer. ..
  61. Race,Treatment and Endometrial Cancer Survival
    Katrina Armstrong; Fiscal Year: 2005
    ..In addition, within each category, we will investigate differences related to primary surgery and adjuvant radiation therapy. ..
  62. EVALUATING USE OF GENETIC INFORMATION: A MODEL PROCESS
    Wylie Burke; Fiscal Year: 2003
    ..5. To conduct an evaluation of the model process within a large health care system. ..
  63. Chk2--Roles in Checkpoint and Breast Tumor Suppression
    Shiaw Yih Lin; Fiscal Year: 2003
    ..We believe that the mechanisms and targets discovered in our studies will be critical for developing more effective approaches in breast cancer therapy in the future. ..
  64. Epithelial-stromal cell interactions in breast cancer
    Kornelia Polyak; Fiscal Year: 2010
    ....